)
KORU Medical Systems (KRMD) investor relations material
KORU Medical Systems Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Business and platform
Enables large-volume subcutaneous drug delivery at home and in clinics, supporting the shift from hospital-based IV therapy to patient-administered care.
Freedom Infusion System serves ~60,000 chronic patients and supports ~2.7M annual recurring infusions; weekly SCIg treatment is typically ongoing for chronic conditions.
Seven SCIg drugs from four major pharmaceutical manufacturers are cleared for use; Freedom60 and FreedomEDGE also have 510(k) clearance and MDR approval for prefilled syringes.
Product mix is ~20% mechanical pumps and ~80% customizable consumables; cited patient adherence rate is 97%.
Market opportunity and pipeline
Large-volume SC opportunity includes a growing SCIg market with <20% penetration versus IVIg, plus 95+ drugs in development at volumes above 10 mL.
Estimated market opportunity is ~$60M in 2025 and ~$138M by 2030; 13 drugs launched during 2020–2026, diversifying the market mainly into oncology.
Pipeline includes eight active new-drug or indication opportunities and nine drugs on the system label; estimated annual infusion volumes include 5.4M for SCIg and <0.25M for non-SCIg drugs.
Near-term opportunities include deferoxamine, Phesgo, Empaveli for FSGS and DGF, and enzyme therapy; estimated launch windows span 0–1, 1–3 and 3–5 years.
Financial performance
FY2025 revenue was $41.1M; FY2026 guidance is $48M–$48.5M, 17–18% YoY growth, 63–64% gross margin, positive adjusted EBITDA and year-end cash above $8M.
YTD 2026 revenue was $35.4M, up 17%; gross margin was 64.0%, up 190 bps, and operating expenses were 64.1% of sales, a 620 bps improvement YoY.
YTD 2026 net loss was $0.3M versus $2.2M; adjusted EBITDA was $2.2M versus $0.1M, while cash usage was $1.5M and included a ~$1M Q2 technology acquisition.
Long-term goals include $100M revenue, accelerated double-digit revenue CAGR, gross margin above 65% and EBITDA margin above 20%.
- $100M shelf expands financing options across equity, debt and warrants.KRMD
Registration filing - Q3 growth and new market initiatives underpin the path toward $100 million in revenue.KRMD
Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum - Q3 revenue and margins rose, returning results to profit as FY26 guidance increased.KRMD
Q3 2026 - Accelerating growth in subcutaneous drug delivery with robust 2026 financial outlook.KRMD
Conference presentation - Guidance for FY2026 targets $47.5–$48.5M revenue and 15–18% growth, driven by innovation and expansion.KRMD
Corporate presentation - Q2 2026 revenue up 18%, gross margin 65.1%, and net income positive on strong global growth.KRMD
Q2 2026 - Strong recurring revenue and pipeline expansion drive double-digit growth in SC drug delivery.KRMD
Investor presentation - Q1 2026 revenue up 22% to $11.8M, improved margins, and strong full-year outlook reaffirmed.KRMD
Q1 2026 - Q3 revenue up 17% to $8.2M, gross margin 63.4%, and guidance raised for 2024.KRMD
Q3 2024
)
)
)
)
)
)
)
)